https://www.globenewswire.com/news-release/2023/10/16/2760573/0/en/Editas-Medicine-Granted-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-for-EDIT-301-for-the-Treatment-of-Severe-Sickle-Cell-Disease.html
CAMBRIDGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that...
editas medicinegrantedfdaregenerativeadvanced
https://www.macrotrends.net/stocks/charts/EDIT/editas-medicine/financial-statements
Ten years of annual and quarterly financial statements and annual report data for Editas Medicine (EDIT). Income statements, balance sheets, cash flow...
editas medicinefinancial statementsmacrotrends
https://www.statnews.com/2025/01/15/jp-morgan-conference-editas-o-neill-strategy/
Jan 15, 2025 - JPM news: "We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to move its gene therapies toward market.
jpmcrisprpioneereditasoutlines
https://www.nasdaq.com/market-activity/stocks/edit/price-earnings-peg-ratios
Get updated information on Editas Medicine, Inc. Common Stock (EDIT) Price/Earnings Ratio (or PE Ratio) and PEG ratio for stock evaluations with Nasdaq.
editas medicinecommon stockpeg ratiosincprice
https://www.biopharmadive.com/news/editas-medical-officer-executive-turnover/618494/
Shares of the gene editing biotech slumped Tuesday on news that chief medical officer Lisa Michaels had joined a growing list of executive departures.
biopharma diveeditasexecutiveshakecontinues
https://www.pharmaceutical-technology.com/data-insights/editas-medicine-files-patent-for-genome-editing-system-components-using-engineered-nucleic-acids/
Discover how Editas Medicine Inc. is revolutionizing genome editing with their patented engineered nucleic acids and RNA-guided nucleases. Explore the...
editas medicinepatent filingnucleic acidsincengineered
https://www.fiercebiotech.com/biotech/editas-shares-boosted-patent-office-rules-favor-broads-crispr-patents
The U.S. Patent and Trademark Office has ruled in favor of the Broad Institute of MIT and Harvard in a dispute over the patents around CRISPR gene editing...
patent officeupdateeditassharesboosted
https://www.fool.com/investing/2021/05/05/what-really-mattered-with-editas-medicines-q1-upda/
It wasn't the biotech's financial performance.
editas medicinereallyupdate
https://www.macrotrends.net/stocks/charts/EDIT/editas-medicine/pre-tax-profit-margin
Editas Medicine pre-tax profit margin from 2015 to 2025. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
editas medicinetax profitpremarginmacrotrends
https://www.macrotrends.net/stocks/charts/EDIT/editas-medicine/roa
Current and historical return on assets (ROA) values for Editas Medicine (EDIT) over the last 10 years. Return on assets can be defined as an indicator of how...
editas medicineroamacrotrends
https://www.fool.com/investing/2023/10/02/better-gene-editing-stock-editas-medicine-vs-crisp/?source=financialcontent&utm_source=financialcontent&utm_medium=feed&utm_campaign=article
The better of the pair should be able to beat Bluebird Bio.
gene editingeditas medicinecrispr therapeuticsbetterstock